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Context: 68Gallium prostate-specific membrane antigen (PSMA) ligand 68Ga-HBED-CC-PSMA
(68Ga-PSMA) is a promising radiotracer for positron emission tomography (PET)/computed
tomography (CT) of prostate cancer.
Objective: To conduct a meta-analysis to evaluate detection rate, diagnostic test accuracy, and
adverse effects of 68Ga-PSMA PET/CT or PET/magnetic resonance imaging (MRI) for staging of
prostate cancer and for restaging of rising prostate-speciﬁc antigen (PSA) after initial treatment.
Evidence acquisition: Following the Preferred Reporting Items for Systematic reviews and
Meta-Analysis (PRISMA) guidelines, our systematic review searched for articles in PubMed and
EMBASE databases from 2012 to July 2016. The reference standard was pathology after biopsy
or surgery. The analyses used a random effect model and a hierarchical summary receiver
operating characteristic model.
Evidence synthesis: Fifteen 68Ga-PSMA PET/CT studies with 1256 patients met the inclusion
criteria. Seven studies of staging PET/CT or PET/MRI detected a regional site of cancer for 203 of
273 patients (74%). Nine studies of restaging PET/CT detected sites of recurrence in 799 of
983 patients (81%) with a 50% detection rate (74 of 147 patients) for restaging PSA of 0.2–0.49
ng/ml and a 53% detection rate (56 of 195 patients) for restaging PSA of 0.50–0.99 ng/ml.
Staging 68Ga-PSMA PET/CT in the studies had higher detection rates of sites in the prostate bed
than restaging 68Ga-PSMA PET/CT (mean 57% vs 14%, p = 0.031, t test). Both staging and
restaging 68Ga-PSMA PET/CT found that a subgroup of the patients had metastatic sites in
pelvic lymph nodes or distant organs. Eight studies of staging PET/CT undertook histologic
correlations. We performed prostate-segment-based analysis speciﬁcally regarding the primary cancer lesion for four of these studies, and patient-based analysis speciﬁcally regarding
pelvic lymph node metastases for four other studies. The pooled sensitivities for staging in the
two groups of studies were 70% and 61%, and the pooled speciﬁcities were 84% and 97%. None of
the studies reported complications from the PET/CT imaging.
Conclusions: 68Ga-PSMA PET/CT has clinical relevance to detect sites of recurrence for patients
with PSA recurrence after radical prostatectomy (RP) with PSA levels less than 1.0 ng/ml.
Patient summary: Choline positron emission tomography (PET)/computed tomography (CT)
can detect sites of recurrent prostate cancer in an earlier phase of prostate-speciﬁc antigen
(PSA) recurrence than bone scans and CT scans, but choline PET/CT is rarely positive for patients
with restaging PSA levels under 1 ng/ml. A new radiotracer called 68Ga-PSMA for PET/CT was
able to detect sites of recurring cancer in up to 50% of patients who had an early rise in PSA
exceeding 0.5 ng/ml after initial radical prostatectomy. The published studies did not report
adverse effects of 68Ga-PSMA PET/CT imaging.
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1.

Introduction

Prostate cancer is the most frequent cancer in men in
Western societies, and in men the cancer mortality is
second to that for lung cancer [1]. Localized prostate cancer
is mainly treated with radical prostatectomy (RP), external
beam radiotherapy (EBRT), or brachytherapy, but up to a
third of patients develop a recurrence [2,3]. A rise of
prostate-specific antigen (PSA) is typically the first indication of recurrence and is called PSA-only recurrence because
patients with PSA <10 ng/ml typically have negative
findings with conventional computed tomography (CT)
scans and 99mTc bone scans. More recently, hybrid choline
positron-emission tomography (PET)/CT allowed reliable
detection of sites of recurrence at PSA levels >1–2 ng/ml
[4,5]. Guidelines recommend a potentially curative treatment of PSA recurrence after RP in the form of salvage
radiotherapy for the prostate bed (SRT) without guidance
from imaging. SRT gives the best results when it is started
while patients have restaging PSA of 0.2–0.5 ng/ml.
Typically up to half of patients develop a second PSA
recurrence during follow-up after SRT, and the development
and application of new and more sensitive PET probes to
guide salvage treatment is a field for ongoing investigations
to improve salvage treatment.
Most prostate cancer cells express prostate-specific
membrane antigen (PSMA), also denoted glutamate carboxypeptidase 2 or N-acetyl-L-aspartyl-L-glutamate peptidase 1 (NAALAD1) [6]. A German group developed a smallmolecule inhibitor for PSMA, Glu-NH-CO-NH-Lys (Ahx){68Ga-(N,N0 -bis-[2-hydroxy-5(carboxyethyl)benzyl]ethylenediamine-N,N0 -diacetic acid}
(68Ga-HBED-CC-PSMA or 68Ga-PSMA-11) [7], referred to
here as 68Ga-PSMA. In 2012, the German group reported
promising findings using this molecule as a PET/CT
radiotracer for patients with prostate cancer [8], and later
meta-analyses confirmed the findings and indicated that
68
Ga-PSMA PET/CT detects prostate cancer better than
radiolabeled choline PET/CT [5,9].
2.

Evidence acquisition

2.1.

Research question

2.2.

the
and
two
the

Outcome measures

We calculated the detection rate as the number of patients
with detected sites in relation to the total number of imaged
patients [11]. We calculated imaging test accuracy for the
detection of lesions in the prostate and pelvic lymph nodes
based on a reference standard with histopathology after
biopsy or RP and pelvic lymph node dissection. We
summarized the side effects following the imaging with
PET/CT or PET/MRI as they were reported in the studies.
2.4.

Search strategy

Our systematic review and meta-analysis followed
Preferred Reporting Items for Systematic Reviews
Meta-Analysis (PRISMA) guidelines [10]. In May 2016,
authors (FEvE and GB) registered a protocol for

systematic review in the PROSPERO register (CRD
42016039690). Our systematic review included original
research studies of staging or restaging with 68Ga-PSMA
PET/CT or PET/MRI. The two authors undertook an
electronic search in PubMed and EMBASE databases. The
PubMed search used medical subject heading (MeSH) terms
and free text words: ((‘‘prostatic neoplasm*’’) [MeSH] OR
(‘‘prostate cancer*’’)) AND ((‘‘positron emission tomography’’) [MeSH] OR (‘‘PET’’)) AND ((‘‘prostate membrane
specific antigen’’) [MeSH] OR (‘‘PSMA’’)) AND ((‘‘*Gallium’’)
[MeSH]) OR (‘‘*Ga’’)). Further, we searched for ongoing
studies in the database ClinicalTrials (ClinicalTrials.gov).
The two reviewers independently screened the titles and
abstracts of the reports and selected original research
articles published in English. Our review included studies
on patients with prostate cancer using 68Ga-PSMA PET/CT
or PET/MRI for initial staging of prostate cancer or for
restaging with rising PSA after the initial treatment. We
excluded articles published before 2012, the founding year
for 68Ga-PSMA, reviews, comments, and studies of laboratory results, studies of neoplasms apart from prostate
cancer, studies of radiotracers apart from 68Ga-PSMA, and
studies that focused on the bioavailability of the radiotracer.
Further, we excluded studies that only reported patients
with a positive 68Ga-PSMA PET/CT because they spuriously
would have increased the pooled detection rates [9], studies
that only undertook 68Ga-PSMA PET/CT for patients with a
negative choline PET/CT because the criterion implied
selection bias, and studies with 20 patients owing to
concerns regarding selection and publication bias and
imprecision. The meta-analysis also excluded studies that
combined staging with restaging, apart from one study
consisting of >200 patients where the smallest patient
group represented <10% of all patients, and one study that
analyzed the two patient groups separately. Where a center
had published several articles of its experience with 68GaPSMA PET/CT, we based our summary of the total number of
examined patients on the article with the most patients, and
our summary of diagnostic test accuracy on another article
because only the replicate article reported the diagnostic
information.
2.3.

We aimed to summarize studies of staging and restaging
68
Ga-PSMA PET/CT or PET/MRI for patients with prostate
cancer regarding detection of localized or metastatic
prostate cancer. A second objective was to summarize
imaging test accuracy of the new PET/CT method using
pathology after biopsy or surgery as the reference standard.
A third objective was to summarize imaging-related side
effects from 68Ga-PSMA PET/CT or PET/MRI.

687

Data collection

From the studies, both reviewers independently extracted
the radiation activity of the 68Ga-PSMA radiotracer, the
uptake time between injection of the radiotracer and
imaging, detection criteria, blinding of nuclear medicine
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physicians for clinical information, and blinding of pathologists for the 68Ga-PSMA PET/CT findings. Both reviewers
also registered the number of patients, median/mean age of
the patients, staging or restaging, initial treatment, median/
mean PSA at the time of PET, and detection rate and imaging
test accuracy with 68Ga-PSMA PET/CT. One of the reviewers
contacted all primary investigators for more information. In
addition, for nine of our studies we compared our extracted
information with that of a meta-analysis published by an
independent team [9].
2.5.

Quality assessment

We assessed risk of bias in the studies according to the
Quality Assessment of Diagnostic Accuracy Studies (QUADAS)-2, as performed in previous reviews [11–13].
2.6.

Meta-analytical methods

Our meta-analysis applied parametric statistic to summarize means  SDs of clinical characteristics, and used t tests to
compare clinical characteristics between two groups of
patients. Preplanned subgroup analysis of patients with
68
Ga-PSMA PET/CT at staging and restaging investigated
whether the two subgroups differed in overall detection rates
and in the regional pattern of detected sites. We summarized
the sensitivity and specificity of the 68Ga-PSMA PET/CT in
studies that used pathology after biopsy or surgery as
reference standard. Our meta-analysis used a random effect
model and a hierarchical summary receiver operating
characteristic (HSROC) model, carried out with Metandi
software and Stata 14.0 (StataCorp, College station, TX,
USA). Metandi provides a pooled estimate of the summary
point with an estimate of the 95% confidence interval (CI) for
the summary point together with a 95% prediction area for the

combined sensitivity and specificity in a future study. A p
value <0.05 indicated statistical significance.
3.

Evidence synthesis

3.1.

Bibliographic search

Searching in PubMed and EMBASE gave 257 reports
including 42 duplicates (Figure 1). By screening titles and
abstracts of 215 unique reports, the two reviewers
independently excluded reviews, comments and replies,
case reports, articles published before 2012, and studies
employing radiotracers other than 68Ga-PSMA. The two
reviewers read the full text of 37 articles and selected
articles according to some of our exclusion criteria. The
reading left 25 studies for qualitative analyses. Our
quantitative analyses excluded all but two studies that
combined staging and restaging 68Ga-PSMA PET/CT, and all
studies consisting of 20 patients.
3.2.

Description of the studies included

The meta-analysis selected 15 studies with 1256 patients
(Table 1) [14–28]. Three studies were prospective cohort
studies [18,23,26], seven studies were retrospective studies
of consecutive selected patients [15–17,19–21,25], and five
studies were retrospective studies of non-random patients
[14,22,24,28]. Mean of the median/mean age for the
patients was 67  3 yr (range, 62–71 yr). Fourteen studies
only used 68Ga-PSMA PET/CT whereas one study reported
both 68Ga-PSMA PET/CT and 68Ga-PSMA PET/MRI [20]. Mean
of the median/mean total radiation activity of 68Ga-PSMA was
172  27 MBq (range, 146–236 MBq) in 11 studies [14–18,22–
24,27,28], whereas one study reported the mean radiation
activity normalized for body weight as 1.9 MBq/kg [20]. Mean

[(Fig._1)TD$IG]
85 reports
through search
in PubMed

172 reports
through search
in EMBASE
42 duplicates

215 reports without duplicates

37 studies assessed for eligibility by
full text reading

178 reviews, case reports,
and studies of other
radiotracers

12 studies excluded after
reading of full text
25 studies included for qualitative
synthesis

15 studies included for quantitative
analysis

10 studies with
staging and restaging and
with small sample size

Fig. 1 – PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) flow diagram representing the selection of studies in this
systematic review.
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Table 1 – Characteristics of the studies
Study

Patients
(n)

Afshar-Oromieh [14]
Ceci [15]
Eiber [16]
Budaus [17]
Fendler [18]
Herlemann [19]
Maurer [20]
Pﬁster [21]
Rauscher [22]
Rhee [23]
Sachpekidis [24]
Van Leeuwen [25]
Van Leeuwen [26]
Verburg [27]
Zamboglou [28]
Total number

319
70
248
30
21
34
130
28
48
20
31
70
30
155
22

Indication
for PET/CT

S+R
R
R
S
S
S+R
S
R
R
S
R
R
S
R
S

Median/mean age
at diagnosis (yr)

Median/mean PSA and
range at PET/CT (ng/ml)

68
67
70
62
NR
67
66
64
71
62
71
67
65
70
69

4.6 (0.1–41395)
1.7 (0.2–32)
2.0 (0.2–59)
8.8 (1.4–376)
NR
35.1 (0.3–363)
11.6 (6.9–24.5)
2.4 (0.04–8)
1.3 (0.8–2.6)
6.1 (3.5–45)
2.0 (0.1–130)
0.2 (0.05–1.0)
8.1 (5.2–10.1)
4.0 (0–2000+)
11.6 (NR)

PET protocol
Median/mean
radiation activity
(MBq or *MBq/kg)

Median/mean
uptake time
(min)

161
146
155
165
192
NR
1.76*
NR
154
150
236
NR
236
190
172

60
60
54
NR
58
60
60
45
57
60
85
45
85
60
60

1256

NR = not reported; R = restaging PET/CT; S = staging PET/CT.

of the median/mean uptake time for 68Ga-PSMA PET/CT was
61  13 min (range, 45–90 min).
The studies evaluated sites by a visual estimate of the
maximum standard uptake value (SUVmax), and many
studies incorporated a reference tissue SUVmax and reported
a site as being positive when SUVmax was higher than that of
the reference tissue. Overall, 1002 of 1256 imaged patients
had a positive site detected by 68Ga-PSMA PET/CT or PET/
MRI. Ten studies, including one replicate study, used a
histology reference standard [17–23,26,28,29]. Two other
studies [14,15] used histology or clinical judgment and
follow-up as reference standard, whereas four further
studies
did
not
report
a
reference
standard
[16,24,25,27]. None of the studies reported side effects of
the 68Ga-PSMA PET/CT or PET/MRI imaging.

Four studies [18,23,28,29] undertook lesion-based analysis and reported imaging test accuracy of staging 68GaPSMA PET/CT to delineate intraproprostatic cancer lesions
based on a histopathology reference standard. One study
used biopsy as the reference standard [28], and the other
three studies used histopathology after RP and lymph node
dissection as the reference standard [18,23,29]. Pooled
sensitivity among these studies was 70% (95% CI: 53–83%)
and pooled specificity was 84% (95% CI: 24–99%). Figure 3
summarizes the HSROC curve for detection of intraprostatic

[(Fig._2)TD$IG]

Patient selection
Index test
Reference standard

3.3.

Quality assessment

Patient flow

Figure 2 summarizes our evaluation of the 15 studies
regarding risk of bias as indicated by QUADAS-2 analysis.
3.4.

0

20

40

60

80

100

Risk of bias (%)

Staging with PET/CT or PET/MRI

Seven studies reported initial imaging with 68Ga-PSMA PET/
CT or PET/MRI before definitive treatment [17–
20,23,26,28]. Six studies examined only 68Ga-PSMA PET/
CT, whereas one study examined both 68Ga-PSMA PET/CT
(35 patients) and 68Ga-PSMA PET/MRI (95 patients)
[20]. The mean of the reported median/mean PSA values
in the studies was 9.3  2.4 ng/ml (range, 6.1–11.8 ng/ml).
68
Ga-PSMA PET/CT or PET/MRI detected sites in 203 of
273 patients (74%), with 163 (60%) patients demonstrating
a site in the prostate bed, 12 (4%) patients demonstrating a site
in pelvic lymph nodes, and 28 (10%) patients demonstrating
sites in more than one region.

Patient selection
Index test
Reference standard
0

20

40
60
Applicability

80

100

Fig. 2 – Quality Assessment of Diagnostic Accuracy Studies (QUADAS)-2
evaluation of the 15 studies. Regarding bias: proportion of studies with
high risk of bias (red), unclear risk of bias (yellow), and low risk of bias
(green). Regarding concerns for applicability: proportion of studies with
high concerns regarding applicability (red), unclear concerns regarding
applicability (yellow), and low concerns regarding applicability (green).
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[(Fig._3)TD$IG]

[(Fig._5)TD$IG]

1.0

Sensitivity

0.8

68

Ga

Histopathology

0.6

cancer positive
FN

0.4

PSMA
TP

PET/CT

27%

positive

12%

FP

3%
0.2
TN
58%

0
1.0

0.4
0.6
Specificity

0.8

0.2

0

Fig. 3 – Hierarchical summary receiver operating characteristic (ROC)
analysis of staging using positron emission tomography imaging with
68
Ga-PSMA for lesion-based analysis regarding test accuracy for
intraprostatic lesions. The size of the circles shows the size of the
studies, the full line shows the ROC curve, the square shows the
summary operating point, the red stippled line shows the 95%
confidence region for the summary point, and the black stippled line
shows the 95% prediction region as a forecast of the sensitivity and
specificity of a future study. 68Ga-PSMA = 68Ga-labeled ligand for
prostate-specific membrane antigen.

lesions in the studies examining correlations with the
histopathology reference standard. Four other studies
undertook patient-based analysis and reported 68Ga-PSMA
PET/CT imaging test staging accuracy specifically for
sampled pelvic lymph node metastases [17,19,20,26]. Pooled
sensitivity for lymph node detection was 61% (95% CI: 47–
72%) and pooled specificity was 97% (95% CI: 85–99%).
Figure 4 summarizes the HSROC curve for detection of pelvic
lymph node metastases in the studies, and Figure 5 shows a
Venn diagram that also summarized diagnostics regarding
pelvic lymph node metastases.

[(Fig._4)TD$IG]
1.0

Sensitivity

0.8
0.6
0.4
0.2
0
1.0

0.8

0.6 0.4
0.2
Specificity

0

Fig. 4 – Hierarchical summary receiver operating characteristic of staging
68
Ga-PSMA positron emission tomography for patient-based analysis
regarding imaging test accuracy for lymph node metastases. Symbols
are the same symbols as in Figure 3. 68Ga-PSMA = 68Ga-labeled ligand
for prostate-specific membrane antigen.

Fig. 5 – Venn diagram for detection with staging 68Ga-PSMA PET of
pelvic lymph node metastases. The circles indicate PET-positive and
histopathology-positive patients. FN = false negative; FP = false positive;
TN = true negative; TP = true positive. 68Ga-PSMA = 68Ga-labeled ligand
for prostate-specific membrane antigen.

3.5.

Restaging with PET/CT

Nine studies reported restaging with 68Ga-PSMA PET/CT for
patients with persisting and rising PSA after initial
treatment. Seven studies undertook only restaging 68GaPSMA PET/CT [15,16,21,22,24,25,27], whereas two studies
included staging and restaging 68Ga-PSMA PET/CT
[14,19]. The mean of the mean/median restaging PSA levels
was 2.3  1.4 ng/ml (range 0.21–4.6 ng/ml). Two studies
reported PSA recurrence after RP [16,26] whereas the other
seven studies reported PSA recurrence after both RP and EBRT.
In these studies the main treatment was RP for 87% of the
patients (450 of 515) and EBRT for 13% of the patients (65 of
515).
Overall, for restaging of PSA-only recurrence, 68Ga-PSMA
PET detected sites of recurrence in 799 of 983 imaged
patients (81%). The studies reported the regional sites of
recurrence for 615 of 755 patients (82%). Of these patients,
79 (10%) patients had sites in the prostate bed, 164 (22%)
patients had sites in pelvic lymph nodes, 100 (13%) patients
had sites in distant organs, and 272 (36%) had sites of
recurrence in several regions. In eight studies
[14,16,24,25,27,30–32], 74 of 147 patients (50%) with
restaging PSA levels of 0.20–0.49 ng/ml had positive sites
of recurrence, as had 56 of 105 patients (53%) with restaging
PSA of 0.50–0.99 ng/ml. Four of the studies examined the
PSA levels according the detected sites. PET-positive
patients had significantly higher PSA than PET-negative
patients [14,15,24,27]. In one of the studies, PET-positive
metastatic lesions in lymph nodes had a larger diameter
than PET-negative metastatic lesions [26].
Two studies undertook patient-based analysis regarding
68
Ga-PSMA PET/CT imaging test accuracy for restaging of
lymph node metastases versus a histologic reference
standard [21,22]. The sensitivities were 87% and 93%, and
the specificities were 93% and 100%. A third study

EUROPEAN UROLOGY FOCUS 4 (2018) 686–693

[(Fig._6)TD$IG]

Detection rate (%)
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40
20
0
T
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Comb

Fig. 6 – Detection rates for regional sites with staging and restaging
68
Ga-PSMA PET/CT. Grey bars show the proportion of patients with
staging 68Ga-PSMA PET/CT or PET/MRI, and orange bars show the
proportion of patients with restaging 68Ga-PSMA PET/CT. 68GaPSMA = 68Ga-labeled ligand for prostate-specific membrane antigen;
PET = positron emission tomography; CT = computed tomograpy;
MRI = magnetic resonance imaging; Comb = sites in more than one of
the regions; M = sites in distant organs; N = sites in pelvic lymph nodes;
T = site in the prostate bed.

undertook only lesion-based analysis and reported histologic verification for 42 patients regarding separate local,
regional, and soft-tissue sites [14]. Thirteen of the patients
had true-positive findings, three patients had false-positive
findings, 19 patients had a combination of true-positive and
true-negative sites, three patients had a combination of
true-positive and false-negative sites, and four patients had
true-negative findings.
68
Ga-PSMA PET/CT for restaging at the time of PSA
recurrence in the studies had higher overall detection rates
than for 68Ga-PSMA PET/CT staging in the studies before
definitive treatment, but the difference was not statistically
significant (mean 78% vs mean 69%, p = 0.52, t test). By
contrast, detection rates for sites in the prostate bed were
significantly higher with staging 68Ga-PSMA PET/CT than
with restaging 68Ga-PSMA PET/CT (mean 57% vs 14%,
p = 0.031, t test, Figure 6).
4.

Discussion

This meta-analysis has added insight into the use of 68GaPSMA PET/CT and PET/MRI for patients with prostate
cancer. All studies reported examinations with PET/CT,
and only one study included a subgroup of patients
examined with PET/MRI. The studies used a protocol for
68
Ga-PSMA PET/CT with a radiation activity generally in the
range 130–170 MBq, an uptake time of approximately
60 min, and interpretation of the imaging based on
SUVmax. For staging PET/CT or PET/MRI, the detection rate
was 70–80%. For restaging PET/CT, the restaging PSA was
positively associated with the detection rate. The detection
rate was 50% even for restaging PSA levels of 0.2–0.49 ng/
ml, 53% for restaging PSA of 0.5–0.99 ng/ml, and was further
increased for higher restaging PSA levels. Both staging and
restaging PSMA PET/CT imaging were able to distinguish
between single sites in the prostate bed, regional lymph
nodes, and distant organs, and sites in more than one of the
regions. The pooled sensitivity for primary or regional
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cancer was 61–70% and the pooled specificity was 84–97%.
The studies did not report adverse effects from the imaging.
For sites in the prostate bed, staging 68Ga-PSMA PET/CT
before the initial treatment of the primary prostate cancer
had a higher detection rate than restaging 68Ga-PSMA PET/
CT after the initial treatment. This was in part because of
debulking of the primary prostate cancer by the initial
treatment, most often RP. A meta-analysis of choline PET/CT
found the same difference between staging and restaging
choline PET/CT [4]. Similarly, both the present metaanalysis of 68Ga-PSMA PET/CT and the meta-analysis of
choline PET/CT found a subgroup of patients who had
metastatic sites in pelvic lymph nodes and distant organs
both at staging and restaging. Such identification of sites
with PET/CT could guide treatment after surgery for men
with persisting or recurrent PSA indicated by PSA monitoring. The consistency between studies with the two radiotracers for PET/CT suggests that the findings are real [33].
This systematic review has summarized detection rates
and imaging test accuracy reported in the literature until
July 2016. Our systematic review applied more rigid
selection criteria than two previous systematic reviews
[5,9]. For this reason the previous systematic reviews and
our present systematic review had an overlap of only nine
studies, and overlap of only one study that used histopathology as the reference standard. The different selections
of studies in the three systematic reviews may have
contributed to the fact that one of the previous systematic
reviews found a 40% pooled detection rate in restaging with
68
Ga-PSMA PET/CT [9].
Use of PSMA PET/CT for prostate cancer is expanding
rapidly and widely. This has consequences for management.
The international TNM tumor classification system classifies patients with PSA recurrence as M0 if they have no
evidence of metastases on imaging, and as M1 if imaging
shows evidence of metastases. Thus the distinction between
M0 and M1 depends on the selection and validation of
imaging methods used for the restaging.
As an alternative to SRT undertaken without guidance
from imaging, a previous meta-analysis [5] proposed an
algorithm that integrated PSMA PET/CT in the imaging of
prostate cancer. However, because up to half the patients
with PSA-only recurrence treated with SRT obtain longterm biochemical recurrence-free survival, restaging with
68
Ga-PSMA PET/CT can only improve outcome for a
subgroup of at-risk patients with PSA-only recurrence. As
shown in our meta-analysis, restaging with 68Ga-PSMA PET/
CT of such patients with restaging PSA <2 ng/ml might
detect sites of recurrence that could be treated with
targeted treatment with curative intent. We therefore
propose that salvage treatment is individualized and guided
by 68Ga-PSMA PET/CT for these patients also.
Our meta-analysis may have impact on research
regarding 68Ga-PSMA PET/CT for patients with prostate
cancer. Three ongoing trials are recruiting patients. Two
trials address staging with 68Ga-PSMA PET: Evaluation of
Gallium-HBED-CC-PSMA Imaging in Prostate Cancer
patients (PSMA PET) (NCT02611882), and 68Ga-PSMA
PET/MRI in Finding Tumors in Patients with Intermediate
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or High-Risk Prostate Cancer Undergoing Surgery
(NCT02678351). A third trial examines restaging with
68
Ga-PSMA PET/CT: 68Ga-PSMA PET-CT Scan for Diagnosis
and Management of Prostate Cancer (PSMA) (NCT02282137).
Other studies compare PSMA and choline as radiotracers for
restaging PET/CT.
Our review has limitations. We only evaluated 68GaPSMA as a radiotracer for PET/CT or PET/MRI although other
PSMA radiotracers are also being investigated [34]. Because
of the small number of studies, their heterogeneity, and
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